Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denintuzumab mafodotin
- Development stage
- Phase 1
- Lead developer
- Skagen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Denintuzumab mafodotin is a humanized monoclonal antibody-drug conjugate (ADC) developed for the treatment of CD19-positive B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. The drug consists of an anti-CD19 monoclonal antibody linked to the cytotoxic agent monomethyl auristatin F (MMAF). Upon binding to CD19 on B cells, the ADC is internalized, releasing MMAF inside the cell. MMAF binds to tubulin and inhibits its polymerization, resulting in G2/M phase cell cycle arrest and apoptosis of tumor cells. Denintuzumab mafodotin was developed by Seattle Genetics and has been evaluated in clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma and ALL[1][4][6].
- Other names
- denintuzumab mafodotinCys-McMMAF
02
Targets
CD19 (B lymphocyte antigen CD19)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on denintuzumab mafodotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denintuzumab mafodotin.